| http://www.w3.org/ns/prov#value | - Dr Harish Iyer, CEO of India-based Shantha Biotech, opines, These guidelines that seem quite broad are a first step in the direction of defining a regulatory pathway for biosimilars in the US. The EU appears further ahead with specific guidelines for multiple categories of products, such as insulin, EPOs and GCSFs.
|
